Risks of Lynch syndrome cancers for MSH6 mutation carriers.

BACKGROUND Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations. Because there have been only a few studies of mutation carriers, their cancer risks are uncertain. METHODS We identified 113 families of MSH6 mutation carriers from five countries that we ascertained through family cancer clinics and population-based cancer registries. Mutation status, sex, age, and histories of cancer, polypectomy, and hysterectomy were sought from 3104 of their relatives. Age-specific cumulative risks for carriers and hazard ratios (HRs) for cancer risks of carriers, compared with those of the general population of the same country, were estimated by use of a modified segregation analysis with appropriate conditioning depending on ascertainment. RESULTS For MSH6 mutation carriers, the estimated cumulative risks to ages 70 and 80 years, respectively, were as follows: for colorectal cancer, 22% (95% confidence interval [CI] = 14% to 32%) and 44% (95% CI = 28% to 62%) for men and 10% (95% CI = 5% to 17%) and 20% (95% CI = 11% to 35%) for women; for endometrial cancer, 26% (95% CI = 18% to 36%) and 44% (95% CI = 30% to 58%); and for any cancer associated with Lynch syndrome, 24% (95% CI = 16% to 37%) and 47% (95% CI = 32% to 66%) for men and 40% (95% CI = 32% to 52%) and 65% (95% CI = 53% to 78%) for women. Compared with incidence for the general population, MSH6 mutation carriers had an eightfold increased incidence of colorectal cancer (HR = 7.6, 95% CI = 5.4 to 10.8), which was independent of sex and age. Women who were MSH6 mutation carriers had a 26-fold increased incidence of endometrial cancer (HR = 25.5, 95% CI = 16.8 to 38.7) and a sixfold increased incidence of other cancers associated with Lynch syndrome (HR = 6.0, 95% CI = 3.4 to 10.7). CONCLUSION We have obtained precise and accurate estimates of both absolute and relative cancer risks for MSH6 mutation carriers.

[1]  Heather Hampel,et al.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Zwinderman,et al.  Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree , 2001, Journal of medical genetics.

[3]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[4]  I. Bernstein,et al.  Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer , 2008, Familial Cancer.

[5]  P. Møller,et al.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) , 2007, Journal of Medical Genetics.

[6]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[7]  John D Potter,et al.  Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[8]  John L Hopper,et al.  Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[10]  H. Morreau,et al.  Diagnostic Approach and Management of Lynch Syndrome (Hereditary Nonpolyposis Colorectal Carcinoma): A Guide for Clinicians , 2006, CA: a cancer journal for clinicians.

[11]  Bernadette Mazurek Melnyk,et al.  Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.

[12]  W. Frankel,et al.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. , 2006, Cancer research.

[13]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[14]  H. Hollema,et al.  Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Grönberg,et al.  Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome , 2005, Clinical genetics.

[16]  Harry Campbell,et al.  Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. , 2006, The New England journal of medicine.

[17]  D. Schaid,et al.  Evidence for autosomal dominant inheritance of prostate cancer. , 1998, American journal of human genetics.

[18]  P. Møller,et al.  Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. , 2004, Gastroenterology.

[19]  G. Petersen,et al.  Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. , 2006, JAMA.

[20]  W. Frankel,et al.  Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. , 2007, Cancer research.

[21]  J. Potter,et al.  The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. , 2008, Gastroenterology.

[22]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[23]  D. Ward,et al.  Diagnostic markers for early detection of ovarian cancer (Clinical Cancer Research (2008) 14, (1065-1072)) , 2008 .

[24]  W J Ewens,et al.  Remarks on ascertainment , 1989, Genetic epidemiology.

[25]  R. Broaddus,et al.  Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Giles,et al.  Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  G. Parmigiani,et al.  Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomothearapy , 2009, Radiation oncology.

[28]  H C van Houwelingen,et al.  Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment , 2005, Journal of Medical Genetics.

[29]  M. von Knebel Doeberitz,et al.  Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Bonaïti‐pellié,et al.  Hereditary non-polyposis colorectal cancer: current risks of colorectal cancer largely overestimated , 2002, Journal of medical genetics.

[31]  A D Carothers,et al.  Cancer risk associated with germline DNA mismatch repair gene mutations. , 1997, Human molecular genetics.

[32]  J. Mecklin,et al.  Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome , 2007, International journal of cancer.

[33]  Daniel J Sargent,et al.  Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. H. Price,et al.  Germline MSH6 mutations are more prevalent in endometrial cancer patient cohorts than Hereditary Non Polyposis Colorectal Cancer cohorts , 2008, The Ulster medical journal.

[35]  S. Thibodeau,et al.  Analysis of hMLH1 and hMSH2 gene dosage alterations in hereditary nonpolyposis colorectal cancer patients by novel methods. , 2005, The Journal of molecular diagnostics : JMD.

[36]  L. Aaltonen,et al.  Cancer risk in mutation carriers of DNA‐mismatch‐repair genes , 1999, International journal of cancer.

[37]  J. Jass.  Hereditary Non-Polyposis Colorectal Cancer: the rise and fall of a confusing term. , 2006, World journal of gastroenterology.

[38]  P. Goodfellow,et al.  Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. , 2004, American journal of human genetics.